login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
HOTH THERAPEUTICS INC (HOTH) Stock News
USA
- NASDAQ:HOTH -
US44148G2049
-
Common Stock
1.62
USD
-0.03 (-1.82%)
Last: 9/30/2025, 8:05:00 PM
1.62
USD
0 (0%)
Pre-Market:
10/1/2025, 7:00:00 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
HOTH Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities
21 days ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities
a month ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
a month ago - By: Benzinga
- Mentions:
BRKR
SLRX
PPCB
LUNG
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
a month ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards
a month ago - By: Benzinga
- Mentions:
SILO
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers
2 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for HT-001 in Europe
2 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins
3 months ago - By: Silo Pharma, Inc.
- Mentions:
SILO
Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market
3 months ago - By: Hoth Therapeutics, Inc.
- Mentions:
SILO
Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty
3 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects
3 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy
3 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth
3 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway
4 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics to Attend 2025 BIO International Convention
4 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases
4 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities
4 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities
5 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers
6 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform
6 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
6 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
6 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours
6 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
6 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
7 months ago - By: Hoth Therapeutics, Inc.
Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
Please enable JavaScript to continue using this application.